Our observation that residual AML cells survived after MLN0128 treatment prompted us to investigate alterations in the parallel signaling networks induced by MLN0128 and to identify potential antagonistic mechanisms upon mTOR inhibition. This evidence concerns the gene MTOR and acute myeloid leukemia.